Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
Background Semaglutide is a glucagon-like peptide-1 (GLP-1) analog treatment for type 2
diabetes (T2D) available in subcutaneous (sc) and oral formulations. Two cardiovascular …
diabetes (T2D) available in subcutaneous (sc) and oral formulations. Two cardiovascular …
Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes
M Husain, AL Birkenfeld, M Donsmark… - … England Journal of …, 2019 - Mass Medical Soc
Background Establishing cardiovascular safety of new therapies for type 2 diabetes is
important. Safety data are available for the subcutaneous form of the glucagon-like peptide …
important. Safety data are available for the subcutaneous form of the glucagon-like peptide …
Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
M Husain, SC Bain, OK Jeppesen… - Diabetes, Obesity …, 2020 - Wiley Online Library
Aim To investigate the effects of semaglutide versus comparators on major adverse
cardiovascular events (MACE: cardiovascular [CV] death, nonfatal myocardial infarction [MI] …
cardiovascular events (MACE: cardiovascular [CV] death, nonfatal myocardial infarction [MI] …
Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: rationale, design and patient baseline characteristics for the PIONEER 6 trial
SC Bain, O Mosenzon, R Arechavaleta… - Diabetes, Obesity …, 2019 - Wiley Online Library
Aims To assess the cardiovascular (CV) safety of oral semaglutide, the first tablet formulation
of a glucagon‐like peptide‐1 receptor agonist. Materials and methods PIONEER 6 is a …
of a glucagon‐like peptide‐1 receptor agonist. Materials and methods PIONEER 6 is a …
Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the …
LA Leiter, SC Bain, I Hramiak, E Jódar… - Cardiovascular …, 2019 - Springer
Background The SUSTAIN 6 trial demonstrated that once-weekly semaglutide (0.5 and 1.0
mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in …
mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in …
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
SP Marso, SC Bain, A Consoli… - … England Journal of …, 2016 - Mass Medical Soc
Background Regulatory guidance specifies the need to establish cardiovascular safety of
new diabetes therapies in patients with type 2 diabetes in order to rule out excess …
new diabetes therapies in patients with type 2 diabetes in order to rule out excess …
Estimated life-years gained free of new or recurrent major cardiovascular events with the addition of semaglutide to standard of care in people with type 2 diabetes …
J Westerink, KS Matthiessen, S Nuhoho… - Diabetes …, 2022 - Am Diabetes Assoc
OBJECTIVE Semaglutide, a glucagon-like peptide 1 receptor agonist, reduced major
adverse cardiovascular events (MACE) in people with type 2 diabetes (T2D) at high risk of …
adverse cardiovascular events (MACE) in people with type 2 diabetes (T2D) at high risk of …
Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6
M Husain, A Consoli, A De Remigis… - Cardiovascular …, 2022 - Springer
Abstract Background Cardiovascular outcome trials (CVOTs) are conducted on a
background of standard of care including metformin. These analyses sought to determine …
background of standard of care including metformin. These analyses sought to determine …
Cardiovascular safety and benefits of semaglutide in patients with type 2 diabetes: findings from SUSTAIN 6 and PIONEER 6
MA Nauck, DR Quast - Frontiers in endocrinology, 2021 - frontiersin.org
To exclude an excess risk of cardiovascular (CV) events, CV outcomes trials (CVOTs) have
assessed the effects of new glucose-lowering therapies, including glucagon-like peptide-1 …
assessed the effects of new glucose-lowering therapies, including glucagon-like peptide-1 …
A population‐adjusted indirect comparison of cardiovascular benefits of once‐weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type …
LM Evans, L Mellbin, P Johansen… - Endocrinology …, 2021 - Wiley Online Library
Introduction Cardiovascular (CV) effects of once‐weekly subcutaneous (sc) semaglutide 0.5
and 1 mg and dulaglutide 1.5 mg are reported in their respective placebo‐controlled …
and 1 mg and dulaglutide 1.5 mg are reported in their respective placebo‐controlled …